Vertex shutters a PhIII cystic fibrosis combo study, shares slip
Shares of Vertex slid Monday afternoon after the company said it will scrap one of its late-stage studies for a combination therapy for cystic fibrosis after it failed to pass muster in a futility analysis.
Vertex $VRTX is halting its study of VX-661 and Kalydeco (ivacaftor) in people with one copy of the F508del mutation and one copy of a mutation that results in minimal CFTR protein function (F508del het/min). The study stumbled in its first phase, without an improvement in lung function.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
